XenoPort — Investor Presentation (October 2014)
45 slides from XenoPort's investor presentation, Oct 16, 2014
Slide 1: XenoPort, Inc. Investor Presentation October 2014
XenoPort, Inc. Investor Presentation October 2014 © Copyright 2014 XenoPort, Inc. All rights reserved. NASDAQ:XNPT Exhibit 99.1
Slide 2: Safe Harbor Language
October 2014 Investor Slide Presentation 2 Safe Harbor Language These slides and the accompanying oral presentation by XenoPort, Inc. contain forward-looking statements that involve risks and uncertainties, including statements relating to the commercial opportunity and value proposition for HORIZAN
Slide 3: XenoPort Overview
October 2014 Investor Slide Presentation 3 XenoPort Overview A commercial-stage biopharmaceutical company with an internally discovered pipeline focused on CNS and dermatology indications Growing revenues from HORIZANT sales from 2 FDA-approved indications. New indication (alcohol use disorder) will
Slide 4: XenoPort Pipeline
October 2014 Investor Slide Presentation 4 ) XenoPort Pipeline GABAPENTIN ENACARBIL Restless Legs Syndrome (RLS) – U.S. Restless Legs Syndrome – Japan Postherpetic Neuralgia (PHN) – U.S. Alcohol Use Disorder (AUD) – U.S. XP23829 Psoriasis Relapsing Forms of MS ARBACLOFEN PLACARBIL (AP) AUD XP21279 A
Slide 5: Financials
5 Investor Slide Presentation October 2014 Financials HORIZANT net sales increased 66% in 2Q vs. 1Q 2014 to $4.9 million $124.9 million of cash, cash equivalents and short- term investments at 6/30/14 $5.0 million in non-dilutive cash in 3Q 2014 associated with AP licensing agreement No debt
Slide 6: HORIZANT (gabapentin enacarbil) Extended-Release Tablets
HORIZANT® (gabapentin enacarbil) Extended-Release Tablets ¢ XenoPort)
Slide 7: HORIZANT product
WODEDHES 0101-8 Semple Horizant’ |) ‘gabapentin enacar hy i i Extended Fk
Slide 8: HORIZANT: XenoPort's First Commercial Product
October 2014 Investor Slide Presentation 7 HORIZANT: XenoPort’s First Commercial Product Approved for moderate-to-severe primary RLS in adults in April 2011 Approved for the management of PHN in adults in June 2012 XenoPort promotional efforts began in June 2013 6 Orange Book listed patents with exp
Slide 9: HORIZANT Different by Design
October 2014 Investor Slide Presentation 8 HORIZANT Different by Design Drug class: alpha-2-delta ligand (gabapentin, pregabalin) Actively transported prodrug of gabapentin • Addresses pharmacokinetic deficiencies of gabapentin Only approved extended-release alpha-2-delta product Not interchangeable
Slide 10: Moderate-to-Severe Primary RLS Market Opportunity in U.S.
October 2014 Investor Slide Presentation 9 Moderate-to-Severe Primary RLS Market Opportunity in U.S. Over 5 million U.S. adults suffer from moderate-to-severe primary RLS Widespread use of dopamine agonists Growing awareness of issues related to dopamine agonist use in treatment of RLS • New treatme
Slide 11: HORIZANT Attributes for RLS
October 2014 Investor Slide Presentation 10 HORIZANT Attributes for RLS First and only non-dopamine agonist approved for the treatment of moderate-to- severe primary RLS in adults Proven effective in relieving RLS symptoms (clinical trial data) Convenient once-a-day dosing No titration required No e
Slide 12: Slide 12
Slide 13: Postherpetic Neuralgia (PHN)
October 2014 Investor Slide Presentation 11 Postherpetic Neuralgia (PHN) Results from damage that occurs to the peripheral nerve fibers during a shingles outbreak Pain associated with PHN can be very intense About 200,000 patients suffer from PHN in the U.S. Clear unmet medical need • ~30% of patien
Slide 14: HORIZANT Attributes for PHN
October 2014 Investor Slide Presentation 12 HORIZANT Attributes for PHN Simple 4-day titration Efficacy as early as one week Pharmacokinetic differentiation • High bioavailability (75%) • Sustained 24-hour gabapentin blood levels Pivotal trial showed 42% of PHN patients experienced >50% reduction in
Slide 15: HORIZANT Commercialization
October 2014 Investor Slide Presentation 13 HORIZANT Commercialization Initial Plan Upon Return of Product Rights • Establish responsiveness quickly and efficiently • Focus on specialists and high prescribing PCPs of RLS and PHN drugs • Personal promotion and marketing efforts focused in ~ 40 territ
Slide 16: HORIZANT Dispensed Tablets per Month
October 2014 Investor Slide Presentation 14 HORIZANT Dispensed Tablets per Month Source: SHA, PHAST 2014 Previous Partner’s Sales Team of ~300-500 XenoPort Sales Team of ~40 Approved Dose: RLS = 1 tablet per day; PHN = 2 tablets per day Currently >85% of prescribed tablets from XenoPort territories
Slide 17: HORIZANT Prescribers and Daily Dose
Investor Slide Presentation October 2014 15 HORIZANT Prescribers and Daily Dose Source: SHA, PHAST 2014 XenoPort Launch & First Promotion of PHN Indication XenoPort Launch & First Promotion of PHN Indication Prescriptions by Specialty % Prescriptions 1200 mg/day* *Source: Healthcare Analytics, a Sym
Slide 18: XenoPort and NIAAA Clinical Trial Agreement
16 October 2014 Investor Slide Presentation XenoPort and NIAAA Clinical Trial Agreement Randomized, double-blind, placebo-controlled trial of the safety and efficacy of HORIZANT in patients who have AUD XenoPort to supply clinical trial material NIAAA will conduct and pay all other expenses associat
Slide 19: XenoPort
XenoPort’)
Slide 20: Slide 20
Slide 21: Slide 21
Slide 22: XP23829 for Potential Treatment of Psoriasis and/or Relapsing Forms of MS
XP23829 for Potential Treatment of Psoriasis and/or Relapsing Forms of MS
Slide 23: Background: Fumaric Acid Ester Products
October 2014 Investor Slide Presentation 18 Background: Fumaric Acid Ester Products FUMADERM mixture of dimethylfumarate (DMF) and monoethyl fumarate salts • Approved in 1990s and widely used for the treatment of psoriasis in Germany TECFIDERA (dimethylfumarate) • Approved in March 2013 in the U.S.
Slide 24: DMF and XP23829 are Prodrugs of MMF
October 2014 Investor Slide Presentation 19 DMF and XP23829 are Prodrugs of MMF XP23829 DMF MMF MMF Promoiety Methanol + + Esterases XP23829 and DMF produce the same active metabolite (MMF) in the body
Slide 25: Potential XP23829 Advantages and Areas of Differentiation
October 2014 Investor Slide Presentation 20 Potential XP23829 Advantages and Areas of Differentiation Lower incidence and/or less severe GI side effects and flushing • Improved compliance; fewer treatment failures Onset and/or magnitude of efficacy • Earlier onset of immunomodulation Dosing frequenc
Slide 26: XenoPort: A Leader in Development of 2nd Generation MMF Prodrugs
October 2014 Investor Slide Presentation 21 XenoPort: A Leader in Development of 2 nd Generation MMF Prodrugs Completed preclinical PK and safety studies including 13-week toxicology studies in 3 animal species. Studies included DMF comparison arms • Demonstrated less skin and GI irritation compared
Slide 27: XP23829 in a Novel Formulation to Potentially Provide Differentiation
October 2014 Investor Slide Presentation 22 XP23829 in a Novel Formulation to Potentially Provide Differentiation • pH-independent delayed-release mechanism to reduce gastric irritation and food effects on pharmacokinetics • Releases XP23829 over 8-10 hours avoiding high local concentrations in uppe
Slide 28: XP23829 Intellectual Property
October 2014 Investor Slide Presentation 23 XP23829 Intellectual Property • Three issued U.S. patents (US8148414, US8778991 and US8785443) including claim covering composition-of-matter of XP23829 (expiration date 2029) • 17 filed patent application families with pending claims including: • Specific
Slide 29: XP23829 Current Development Plan
24 October 2014 Investor Slide Presentation XP23829 Current Development Plan Conducting Phase 2 psoriasis study to assess the effect of dose and dosing regimen on efficacy, tolerability, safety and immune cell modulation of XP23829 • Trial initiated June 2014 • Top-line results expected in 3Q 2015 •
Slide 30: XP23829 Phase 2 Clinical Trial in Psoriasis Patients
Study Design Number of Sites Number of Subjects Primary Endpoint October 2014 Investor Slide Presentation 25 400 mg BID Placebo 800 mg QD 400 mg QD XP23829 Phase 2 Clinical Trial in Psoriasis Patients Randomized, double-blind, multicenter, parallel group, placebo-controlled, dose-finding efficacy an
Slide 31: Similar Dose Response for TECFIDERA in Psoriasis & Relapsing Forms of MS
October 2014 Investor Slide Presentation 26 Similar Dose Response for TECFIDERA in Psoriasis & Relapsing Forms of MS Phase 2 Psoriasis Study Biogen Press Release 2004 Langner, J Am Acad Dermatol 2005 Week 12 Phase 2 Relapsing Forms of MS Study Kappos, Lancet 2008
Slide 32: Psoriasis is Prevalent, Reduces Quality of Life and is an Economic Burden
October 2014 Investor Slide Presentation 27 Epidemiology Economic Burden Psoriasis is Prevalent, Reduces Quality of Life and is an Economic Burden to Health Systems • Worldwide psoriasis prevalence rates vary from 0.6% to 4.8% • In the U.S., it is estimated that direct costs on health care approach
Slide 33: Oral Therapy Market Share for Moderate and Severe Psoriasis Differs in U.S. and Germany
October 2014 Investor Slide Presentation 28 Oral Therapy Market Share for Moderate and Severe Psoriasis Differs in U.S. and Germany * Assumes no arthritic involvement Sources: Back Bay Physician Interviews, DataMonitor 2013 Treatment Flow and Physician Quantitative Survey U.S. • Orals have 40-50% ma
Slide 34: Desired Product Positioning for XP23829 in Psoriasis
October 2014 Investor Slide Presentation 29 Desired Product Positioning for XP23829 in Moderate-to-Severe Chronic Plaque-Type Psoriasis Safety/Tolerability Unfavorable Favorable Qualitative Positioning Efficacy similar to FUMADERM (PASI 75 = 40-50%) with favorable tolerability and long-term safety D
Slide 35: Oral Treatments for Relapsing Forms of MS
October 2014 Investor Slide Presentation 30 Oral Treatments for Relapsing Forms of MS 2Q 2014 Sales U.S. Ex-U.S. $585M $115M $91M $27M $284M $322M Source: Symphony Health Solutions, PHAST Prescription Monthly, April 2013 – August 2014 1% market share is ~$100M in annual U.S. product sales at current
Slide 36: XenoPort
¢ XenoPort)
Slide 37: Slide 37
Slide 38: Slide 38
Slide 39: Future Opportunities: XP21279 for Parkinson's Disease, AP for Alcohol Use Disorder
FUTURE OPPORTUNITIES XP21279 for Parkinson’s Disease AP for Alcohol Use Disorder
Slide 40: Slide 40
Slide 41: XP21279 Phase 2 Study in Advanced Parkinson's Patients
October 2014 Investor Slide Presentation 33 XP21279 Phase 2 Study in Advanced Parkinson’s Patients Achieved levodopa levels with XP21279/Carbidopa tablet within the target therapeutic window Minimal Fluctuation in Levodopa Blood Levels
Slide 42: FDA Agreements For Potential XP21279 Phase 3 Program
October 2014 Investor Slide Presentation 34 FDA Agreements For Potential XP21279 Phase 3 Program A single successful pivotal 12-week Phase 3 study comparing optimized doses of XP21279 to SINEMET could support approval for treatment of patients with advanced Parkinson’s disease with motor fluctuation
Slide 43: AP Agreement with Reckitt Benckiser Pharmaceuticals
October 2014 Investor Slide Presentation 35 AP Agreement with Reckitt Benckiser Pharmaceuticals Exclusive world-wide rights granted to Reckitt Benckiser Pharmaceuticals • Proven leader in commercialization of addiction treatments, e.g., SUBOXONE Planned initial development focus: AUD $20 million up-
Slide 44: XenoPort Anticipated Milestones
October 2014 Investor Slide Presentation 36 XenoPort Anticipated Milestones HORIZANT • Growing net sales in U.S. and royalties in Japan • Additional ex-U.S. partnership(s) • FDA agreement of AUD development plan • Initiation of AUD pivotal study in 1H 2015 XP23829 • Top-line results of Phase 2 psori
Slide 45: © Copyright 2014 XenoPort, Inc. All rights reserved. ******************* ******************* ******************* ****…
© Copyright 2014 XenoPort, Inc. All rights reserved. NASDAQ:XNPT ******************* ******************* ******************* ******************* *******************